Karim Boudadi, M.D.

Headshot of Karim Boudadi
  • Assistant Professor of Oncology

Languages: English, French, Spanish


Anemias, Blood Disorders, Esophageal Cancer, Head and Neck Cancers, Head and Neck Tumors, Hematology, Medical Oncology, Oncology, Sarcoma ...read more

Research Interests



Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8893 | Fax: 410-614-9334

Sibley Memorial Hospital

5255 Loughboro Road NW
Johns Hopkins Kimmel Cancer Center
Washington, DC 20016 map
Phone: 202-660-6500 | Fax: 202-660-6501


Karim Boudadi, M.D., is a medical oncologist and hematologist with the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, D.C., and an assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine.

Listen to Dr. Boudadi’s Cancer Matters podcast episode to learn more about his work.

Dr. Boudadi has expertise in treating cancers of the head and neck, including salivary gland cancers, as well as cancers of the esophagus, and bone and soft tissue sarcomas. Having completed dual training in medical oncology and hematology at Johns Hopkins University, Dr. Boudadi also treats patients with benign hematologic conditions or non-cancer related blood disorders, such as anemia, low blood counts, bleeding disorders, and clotting disorders. 

Dr. Boudadi earned his medical degree from the University of Rochester School of Medicine. He completed a residency in internal medicine at the University of Michigan in Ann Arbor, MI, and went on to serve as a clinical lecturer in the Department of Internal Medicine at the University of Michigan Medical School before joining Johns Hopkins. He then completed dual fellowship training in both hematology and medical oncology at the Johns Hopkins University School of Medicine. Dr. Boudadi's research during his fellowship focused on prostate cancer and immunotherapy.

Dr. Boudadi is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American College of Physicians, and the American Medical Association. He is also a member of the Hematology and Oncology Fellowship Selection Committee at The Johns Hopkins University School of Medicine. 

Dr. Boudadi has extensive clinical trial development experience and has published his work in peer-reviewed journals. His primary research interest is immunotherapy.

...read more


  • Assistant Professor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Upper Aerodigestive Cancer



  • MD; University of Rochester School of Medicine and Dentistry (2010)


  • Internal Medicine; University of Michigan Health System (2013)


  • Hematology and Oncology; Johns Hopkins University School of Medicine (2017)

Board Certifications

  • American Board of Internal Medicine (Hematology) (2017)
  • American Board of Internal Medicine (Internal Medicine) (2013)
  • American Board of Internal Medicine (Medical Oncology) (2017)

Research & Publications

Selected Publications

View all on PubMed

Boudadi K. Adjuvant Chemotherapy and Novel Therapeutics. Fakhry/Pazoki/Kiess/Eisele, Oral Cancer: Evaluation, Therapy, and Rehabilitation. Thieme USA. 2021

Boudadi K, Suzman D, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White J, Silberstein J, Sullivan R, Dowling D, Harb R, Nirschl T, Veeneman B, Tomlins S, Wang Y, Jendrisak A, Graf R, Dittamore R, Carducci M, Eisenberger M, Haffner M, Meeker A, Eshleman J, Luo J, Velculescu VE, Drake C, Antonarakis E. Ipilimumab plus Nivolumab and DNA-Repair Defects in AR-V7-Expressing Metastatic Prostate Cancer. Oncotarget. 2018 Jun 19;9(47):28561-28571

Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, Dowling D, Harb R, Schonhoft J, Jendrisak A, Carducci MA, Eisenberger MA, Eshleman JR, Luo J, Drake CG, Pardoll DM, Antonarakis ES. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. Prostate. Prostate. 2021 May;81(6):326-338. doi: 10.1002/pros.24110. Epub 2021 Feb 26.

Park JC, Durbeck J, Boudadi K, Ho WJ, Kang H. The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. Oral Oncol. 2020 Sep;108:104935. doi: 10.1016/j.oraloncology.2020.104935. Epub 2020 Aug 10

Cheung LS, Chen L, Oke TF, Schaffer TB, Boudadi K, Ngo JT, Gross JM, Kemberling H, Diaz LA, Lipson E, Sidhom JW, Taube J, Anders R, Pardoll DM, Le DT, Meyer CF, Llosa N. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. J Immunother Cancer. 2021 Jun;9(6):e002345. doi: 10.1136/jitc-2021-002345. PMID: 34103354

Activities & Honors


  • American Medical Association


  • American College of Physicians

    Associate Member

  • American Society of Clinical Oncology


  • American Society of Hematology


Videos & Media

Recent News Articles and Media Coverage

Cancer Matters Podcast: Dr. Bill Nelson discussing the treatment of HPV related head and neck cancers, Johns Hopkins Kimmel Cancer Center Podcasts (May 23, 2019)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button